Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Metehan Ozen is active.

Publication


Featured researches published by Metehan Ozen.


Expert Opinion on Biological Therapy | 2015

Probiotics for the prevention of pediatric upper respiratory tract infections: a systematic review

Metehan Ozen; Gonca Sandal; Ener Cagri Dinleyici

Background: Acute upper respiratory tract infections (URTIs) contribute substantially to pediatric morbidity and mortality worldwide. Prevention of these infections in childhood is a very important public health challenge. Previous systematic reviews, including both adult and childhood populations, have reported that probiotics seem promising, but with modest evidence. This study aimed to focus on prophylactic probiotic use in the prevention of URTIs in childhood. Methods: Relevant trials on two databases were identified in a systematic review, from inception to June 2014. Study selection, data extraction and quality assessment were carried out by two reviewers. In this review, the effects of probiotics, particularly the Lactobacillus and Bifidobacterium strains, on the incidence and symptom scores of URTI in otherwise healthy children were evaluated for the first time. This review comprises 14 randomized controlled trials (RCTs) applied to a pediatric population with high-quality methodology. Results: This systematic review suggests that probiotics in immunocompetent children have a modest effect both in diminishing the incidence of URTIs and the severity of the infection symptoms. Conclusions: At least one beneficial effect of prophylactic probiotic was observed in the majority of RCTs. Even a minimal reduction of 5 – 10% in the incidence of URTIs would have an important clinical and economic mpact on societies. Furthermore, the long-term administration of probiotics appeared to have a good safety profile in childhood and none of the studies reported any serious adverse events related to the probiotic strain.


Beneficial Microbes | 2015

The history of probiotics: the untold story

Metehan Ozen; Ener Cagri Dinleyici

Probiotic, a word derived from Latin, means for life. A long time before the awareness of probiotic microorganisms, fermented products, such as beer, bread, wine, kefir, kumis and cheese had been very frequently used for nutritional and therapeutic purposes. It is widely believed that fermented products were probably found, or better to say, discovered spontaneously. The legend tells that yoghurt is most likely resulted from a fermentation process within the animal skin bags used for transportation of water and milk in regions with low humidity and high temperatures (Middle Asia and Middle East). The history of probiotics goes paralel with the evolution of human race and, thanks to the sophisticated techniques at the moment, can be traced back to the ancient times, nearly 10,000 years ago. The aims of this review are to highlight the important events for probiotic history, to correct the widely available anonymous misinformation in the literature and to remind to the readers important characters in its history.


Beneficial Microbes | 2015

Saccharomyces boulardii CNCM I-745 reduces the duration of diarrhoea, length of emergency care and hospital stay in children with acute diarrhoea.

Ener Cagri Dinleyici; Ates Kara; N. Dalgic; Zafer Kurugöl; V. Arica; O. Metin; E. Temur; O. Turel; S. Guven; Olcay Yasa; S. Bulut; G. Tanir; A.S. Yazar; A. Karbuz; Mesut Sancar; M. Erguven; G. Akca; Makbule Eren; Metehan Ozen; Yvan Vandenplas

Evidence from the literature has shown that Saccharomyces boulardii provides a clinically significant benefit in the treatment of acute infectious diarrhoea in children. In this multicentre, randomised, prospective, controlled, single blind clinical trial performed in children with acute watery diarrhoea, we aimed to evaluate the impact of S. boulardii CNCM I-745 in hospitalised children, in children requiring emergency care unit (ECU) stay and in outpatient settings. The primary endpoint was the duration of diarrhoea (in hours). Secondary outcome measures were duration of hospitalisation and diarrhoea at the 3(rd) day of intervention. In the whole study group (363 children), the duration of diarrhoea was approximately 24 h shorter in the S. boulardii group (75.4±33.1 vs 99.8±32.5 h, P<0.001). The effect of S. boulardii (diarrhoea-free children) was observed starting at 48 h. After 72 h, only 27.3% of the children receiving probiotic still had watery diarrhoea, in contrast to 48.5% in the control group (P<0.001). The duration of diarrhoea was significantly reduced in the probiotic group in hospital, ECU and outpatient settings (P<0.001, P<0.01 and P<0.001, respectively). The percentage of diarrhoea-free children was significantly larger after 48 and 72 h in all settings. The mean length of hospital stay was shorter with more than 36 h difference in the S. boulardii group (4.60±1.72 vs 6.12±1.71 days, P<0.001). The mean length of ECU stay was shorter with more than 19 h difference in the probiotic group (1.20±0.4 vs 2.0±0.3 days, P<0.001). No adverse effects related to the probiotic were noted. Because treatment can shorten the duration of diarrhoea and reduce the length of ECU and hospital stay, there is likely a social and economic benefit of S. boulardii CNCM I-745 in adjunction to oral rehydration solution in acute infectious gastroenteritis in children.


American Journal of Infection Control | 2016

Health care-associated infection surveillance in a tertiary neonatal intensive care unit: A prospective clinical study after moving to a new building.

Ceyhun Cura; Metehan Ozen; Aybüke Akaslan Kara; Gülsüm Alkan; Emel Sesli Çetin

BACKGROUNDnThere are very few prospective clinical studies on neonatal health care-associated infection (HAI) surveillance. HAI surveillance helps reduce not only mortality, but also morbidity, length of hospital stay, and health care costs.nnnMETHODSnThis prospective clinical study covered a period of 12 months in a tertiary neonatal intensive care unit (NICU). HAI rates were calculated using different denominators: number of patients hospitalized in the NICU, number of patient-days, and number of specific device-days.nnnRESULTSnThe HAI rate was 18%, and the incidence density was 17/1,000 patient-days. The most common HAI was bloodstream infection (n = 34; 50%). The most common pathogen was coagulase-negative staphylococci (CoNS; 54.9%) in gram-positive bacteria and in general. Methicillin resistance was 96.4% for CoNS. Klebsiella spp (13.7%) was the most common gram-negative bacteria. Extended-spectrum β-lactamase positivity was 14.3% for Klebsiella spp and 25% for Escherichia coli. HAI-related mortality was 0.3%.nnnCONCLUSIONSnNICUs should perform their own HAI surveillance with prospective clinical design. Attention paid to handwashing, disinfection and sanitizing, complying with the terms of asepsis, extending in-service training, increasing the number of medical staff, preventing frequent changes in health care staff positions, and improving physical environmental conditions in NICUs might eventually decrease HAI rates.


Vaccine | 2015

Children with breakthrough varicella infection requiring hospitalization in Turkey (VARICOMP Study 2008–2013)

Ener Cagri Dinleyici; Zafer Kurugöl; Ates Kara; Hasan Tezer; Mehmet Ali Tas; Ekrem Guler; Olcay Yasa; İlker Devrim; Ergin Çiftçi; Halil Özdemir; Ayper Somer; Metehan Ozen; Gulnar Sensoy; Nazan Dalgic; Emre Alhan

INTRODUCTIONnVaricella in previously immunized individuals, known as breakthrough varicella. While the majority of breakthrough cases are mild, some may be severe, requiring hospitalization in previously healthy children or children with an underlying condition.nnnMETHODSnThis report, as a part of the prospective national pediatric varicella hospitalizations study (including 29 centers, represent 50% of pediatric population) in Turkey, is aimed to evaluate breakthrough varicella infection requiring hospitalization before the routine use of single-dose live varicella vaccine in national program from 2008 to 2013 (<10% of the pediatric age group received a single-dose vaccine).nnnRESULTSnIn the time period, 1939 children were hospitalized due to varicella infection in Turkey; 36 children (20 boys, 16 girls, mean age 68.0+37.6 months, all received single dose live varicella vaccine) with breakthrough varicella infection. Breakthrough varicella infection might be severe in previously healthy children (61.1%) and children with immune-compromising conditions (38.9%). The time elapsed between vaccination and hospitalization was approximately 5 years, and neurological complications, mainly encephalitis and meningitis, were the most common reason for hospitalization in previously healthy children.nnnCONCLUSIONnPediatric breakthrough varicella requiring hospitalization have been seen in Turkey, is mainly observed in previously healthy children at 5 years after a single-dose varicella vaccine. The varicella vaccine has been implemented as part of the National Immunization Program in Turkey in 2013 (a single dose at age 12 months). Further surveillance in the same settings could evaluate the effectiveness of national immunization with single-dose varicella vaccine at 12 months of age and potential need for second dose of vaccine.


Journal of global antimicrobial resistance | 2018

Antifungal consumption, indications and selection of antifungal drugs in pediatric tertiary hospitals in Turkey: Results from the first national point prevalence survey

İlknur Çağlar; İlker Devrim; Halil Özdemir; Zümrüt Şahbudak; Gülsüm Sönmez; Ayse Buyukcam; Belgin Gülhan; Ahu Kara; Deniz Aygun; Nuri Bayram; Solmaz Celebi; Benhur Sirvan Cetin; Merve Iseri Nepesov; Ayşe T Yilmaz; Eda Kepenekli; Dilek Yılmaz Çiftdoğan; Manolya Acar; Burcu Cura Yayla; Canan Okumuş; Zafer Ecevit; Nevin Hatipoglu; Necdet Kuyucu; Muhammed Kosker; Semra Sen; Adem Karbuz; Murat Sütçü; Burcu Bursal Duramaz; Metehan Ozen; Ergin Çiftçi; Derya Alabaz

OBJECTIVESnThe aim of this point prevalence survey was to evaluate the consumption, indications and strategies of antifungal therapy in the paediatric population in Turkey.nnnMETHODSnA point prevalence study was performed at 25 hospitals. In addition to general data on paediatric units of the institutes, the generic name and indication of antifungal drugs, the presence of fungal isolation and susceptibility patterns, and the presence of galactomannan test and high-resolution computed tomography (HRCT) results were reviewed.nnnRESULTSnA total of 3338 hospitalised patients were evaluated. The number of antifungal drugs prescribed was 314 in 301 patients (9.0%). Antifungal drugs were mostly prescribed in paediatric haematology and oncology (PHO) units (35.2%), followed by neonatal ICUs (NICUs) (19.6%), paediatric services (18.3%), paediatric ICUs (PICUs) (14.6%) and haematopoietic stem cell transplantation (HSCT) units (7.3%). Antifungals were used for prophylaxis in 147 patients (48.8%) and for treatment in 154 patients (50.0%). The antifungal treatment strategy in 154 patients was empirical in 77 (50.0%), diagnostic-driven in 29 (18.8%) and targeted in 48 (31.2%). At the point of decision-making for diagnostic-driven antifungal therapy in 29 patients, HRCT had not been performed in 1 patient (3.4%) and galactomannan test results were not available in 12 patients (41.4%). Thirteen patients (8.4%) were receiving eight different antifungal combination therapies.nnnCONCLUSIONnThe majority of antifungal drugs for treatment and prophylaxis were prescribed in PHO and HSCT units (42.5%), followed by ICUs. Thus, antifungal stewardship programmes should mainly focus on these patients within the availability of diagnostic tests of each hospital.


Frontiers in Microbiology | 2018

Time Series Analysis of the Microbiota of Children Suffering From Acute Infectious Diarrhea and Their Recovery After Treatment

Ener Cagri Dinleyici; Daniel Martínez-Martínez; Ates Kara; Adem Karbuz; Nazan Dalgic; Ozge Metin; Ahmet Sami Yazar; Sirin Guven; Zafer Kurugöl; Ozden Turel; Mehmet Kucukkoc; Olcay Yasa; Makbule Eren; Metehan Ozen; Jose Manuel Martí; Carlos P. Garay; Yvan Vandenplas; Andrés Moya

Gut microbiota is closely related to acute infectious diarrhea, one of the leading causes of mortality and morbidity in children worldwide. Understanding the dynamics of the recovery from this disease is of clinical interest. This work aims to correlate the dynamics of gut microbiota with the evolution of children who were suffering from acute infectious diarrhea caused by a rotavirus, and their recovery after the administration of a probiotic, Saccharomyces boulardii CNCM I-745. The experiment involved 10 children with acute infectious diarrhea caused by a rotavirus, and six healthy children, all aged between 3 and 4 years. The children who suffered the rotavirus infection received S. boulardii CNCM I-745 twice daily for the first 5 days of the experiment. Fecal samples were collected from each participant at 0, 3, 5, 10, and 30 days after probiotic administration. Microbial composition was characterized by 16S rRNA gene sequencing. Alpha and beta diversity were calculated, along with dynamical analysis based on Taylors law to assess the temporal stability of the microbiota. All children infected with the rotavirus stopped having diarrhea at day 3 after the intervention. We observed low alpha diversities in the first 5 days (p-value < 0.05, Wilcoxon test), larger at 10 and 30 days after probiotic treatment. Canonical correspondence analysis (CCA) showed differences in the gut microbiota of healthy children and of those who suffered from acute diarrhea in the first days (p-value < 0.05, ADONIS test), but not in the last days of the experiment. Temporal variability was larger in children infected with the rotavirus than in healthy ones. In particular, Gammaproteobacteria class was found to be abundant in children with acute diarrhea. We identified the microbiota transition from a diseased state to a healthy one with time, whose characterization may lead to relevant clinical data. This work highlights the importance of using time series for the study of dysbiosis related to diarrhea.


International Journal of Rheumatic Diseases | 2015

Kawasaki disease in a 9-year old girl presenting with febrile cholestasis: case report and review of literature

Tugba Koca; Nagehan Aslan; Aybüke Akaslan Kara; Ayhan Pektas; Metehan Ozen; Mustafa Akcam

Kawasaki disease is a systemic vasculitis that develops during childhood, especially in those younger than 5 years. Gastrointestinal involvement does not belong to the classic diagnostic criteria. We reported here, a 9‐year old girl who presented with febrile cholestasis, and developed a medium right coronary artery aneurysm despite intravenous immunoglobulin administration on the 9th day of fever. Hepatobiliary ultrasonographic evaluation revealed normal findings. Seroimmunologic markers of cholestasis were negative. Her clinical feature was ameliorated shortly after a second dose of intravenous immunoglobulin administration. We consider that a high index of suspicion of Kawasaki disease could prevent delayed diagnosis and complications.


Turkiye Klinikleri Journal of Pediatrics | 2016

Visceral Leishmaniasis with Splenic Nodules: Case Report

Gülsüm Alkan; Aybüke Akaslan Kara; Metehan Ozen


Beneficial Microbes | 2015

Foreword: All things considered about probiotics, prebiotics and ıntestinal microbiota in children – from bench to bedside

Metehan Ozen; Ener Cagri Dinleyici

Collaboration


Dive into the Metehan Ozen's collaboration.

Top Co-Authors

Avatar

Aybüke Akaslan Kara

Süleyman Demirel University

View shared research outputs
Top Co-Authors

Avatar

Ener Cagri Dinleyici

Eskişehir Osmangazi University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Nagehan Aslan

Süleyman Demirel University

View shared research outputs
Top Co-Authors

Avatar

Olcay Yasa

Istanbul Medeniyet University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Gülsüm Alkan

Süleyman Demirel University

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge